Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 1
1996 1
1997 1
1998 1
1999 1
2000 1
2001 2
2002 1
2003 3
2004 1
2007 2
2010 1
2012 1
2013 1
2016 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
Treatment with lenalidomide in myelodysplastic syndromes with deletion 5q: results from the Dutch named patient program.
Abouyahya I, Alhan C, Westers TM, te Boekhorst PA, Kappers-Klunne MC, Coenen JL, Heyning FH, Huls GA, de Wolf JT, Imholz AL, Koene HR, Veth G, de Kruijf EJ, Muus P, Planken EV, Segeren CM, Vasmel WL, van der Velden AM, Velders GA, Koedam J, Ossenkoppele GJ, van de Loosdrecht AA. Abouyahya I, et al. Among authors: segeren cm. Leuk Lymphoma. 2013 Apr;54(4):874-7. doi: 10.3109/10428194.2012.728702. Epub 2012 Sep 28. Leuk Lymphoma. 2013. PMID: 22971215 No abstract available.
[Multiple myeloma; treatment in the year 1998].
Lokhorst HM, Sonneveld P, Wijermans PW, Segeren CM. Lokhorst HM, et al. Among authors: segeren cm. Ned Tijdschr Geneeskd. 1998 Jul 11;142(28):1596-602. Ned Tijdschr Geneeskd. 1998. PMID: 9763840 Review. Dutch.
A cost-utility analysis comparing intensive chemotherapy alone to intensive chemotherapy followed by myeloablative chemotherapy with autologous stem-cell rescue in newly diagnosed patients with stage II/III multiple myeloma; a prospective randomised phase III study.
van Agthoven M, Segeren CM, Buijt I, Uyl-de Groot CA, van der Holt B, Lokhorst HM, Sonneveld P. van Agthoven M, et al. Among authors: segeren cm. Eur J Cancer. 2004 May;40(8):1159-69. doi: 10.1016/j.ejca.2004.01.019. Eur J Cancer. 2004. PMID: 15110879 Clinical Trial.
Vincristine, doxorubicin and dexamethasone (VAD) administered as rapid intravenous infusion for first-line treatment in untreated multiple myeloma.
Segeren CM, Sonneveld P, van der Holt B, Baars JW, Biesma DH, Cornellissen JJ, Croockewit AJ, Dekker AW, Fibbe WE, Löwenberg B, van Marwijk Kooy M, van Oers MH, Richel DJ, Schouten HC, Vellenga E, Verhoef GE, Wijermans PW, Wittebol S, Lokhorst HM. Segeren CM, et al. Br J Haematol. 1999 Apr;105(1):127-30. Br J Haematol. 1999. PMID: 10233375 Free article. Clinical Trial.
Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
Wu KL, Beverloo B, Lokhorst HM, Segeren CM, van der Holt B, Steijaert MM, Westveer PH, Poddighe PJ, Verhoef GE, Sonneveld P; Dutch-Belgian Haemato-Oncology Cooperative Study Group (HOVON); Dutch Working Party on Cancer Genetics and Cytogenetics (NWCGC). Wu KL, et al. Among authors: segeren cm. Br J Haematol. 2007 Feb;136(4):615-23. doi: 10.1111/j.1365-2141.2006.06481.x. Br J Haematol. 2007. PMID: 17223915 Free article. Clinical Trial.
17 results